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The coronavirus disease (COVID-19) pandemic has affected an estimated 16million
persons and caused 0.6 million deaths worldwide by September 2020. The pandemic
has led to a rush to repurpose existing drugs, although the underlying evidence base is of
variable quality. The improving knowledge of the virology and clinical presentation of
COVID-19 is leading to a broadening pool of potential pharmacological targets. The aim of
this review is to describe regulatory and pharmacological aspects of drug repurposing and
to identify drugs proposed for repurposing in COVID-19 based on registered clinical trials,
discussing the evidence to support their use in the treatment of this disease. The
challenges of the correct interpretation of existing pre-clinical/clinical evidence as well
as the generation of new evidence concerning drug repurposing in COVID-19 will also be
discussed.
Clinical Trial Registration:
https://clinicaltrials.gov, identifier NCT04321174, NCT04342663, NCT04280705,
NCT04244591, NCT04359329, NCT04348695, NCT04304313, NCT043505931
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INTRODUCTION
To date, the global coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has led tomore than 16 million infected patients
and more than 600,000 deaths worldwide by September 2020 (European Centre for Disease
Prevention and Control, 2020). To date, only remdesivir, an investigational antiviral compound,
has received a conditional marketing authorization from the European Commission for the
treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who
require supplemental oxygen (European Medicines Agency, 2020a). Remdesivir has also been
approved in Japan (Gilead, 2020) and has received Emergency Use Authorization in the United
States from the Food and Drug Administration (Food and Drug Administration, 2020a). No other
treatments have been approved to date.
There is great interest in drug repurposing (also known as repositioning or rediscovery) to
accelerate the identification of drugs that can cure or prevent COVID-19. The value of drug
repurposing is to speed up the traditional process of drug discovery by identifying a novel clinical use
for drugs that have already proven to be safe and effective in humans and are approved for other
indications. This strategy can also reduce the costs required for the development of new drugs, with
notable savings in preclinical phase I and II (Pushpakom et al., 2018). The rationale of drug
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repurposing lies in the fact that the samemolecular pathways may
be involved in different diseases (Oprea et al., 2011). One of the
key drivers for the repositioning of drugs is the serendipitous
discovery of pharmacological activity on new targets, which
would then suggest that a new possible indication of use
(Pushpakom et al., 2018). Some classical examples of
serendipity-based drug repurposing are thalidomide,
originally developed for the treatment of morning sickness
in pregnant women and now used in multiple myeloma
(Jacobson, 2000), sildenafil, initially conceived for the
treatment of angina and hypertension and today used for
the treatment of erectile dysfunction (Ghofrani et al., 2006)
and amantadine, an antiviral which was originally indicated
for influenza and was then used to treat Parkinson’s disease
(Lee and Kim, 2016).
Repurposing has several implications in the drug regulatory
setting as well as in the scientific setting, especially if it occurs
during a public health emergency such as the COVID-19
pandemic. In this review, challenges for drug repurposing
in the COVID-19 pandemic era will be described. In
addition, drugs proposed as candidates for repurposing in
COVID-19 will be identified and the rationale behind their
use will be discussed.
DRUG REPURPOSING FROM A
REGULATORY PERSPECTIVE
Repurposing officially falls into a number of categories, bearing in
mind that physicians in most countries have the right to use drugs
outside the existing approved label and frequently do. However,
“off-label” use is often frowned upon by regulatory drug agencies
and scientific societies, as the effectiveness and safety of drugs for
off-label indications may not be established. In most cases, to have
a new indication approved, substantial investment is required. A
patent is essential for the sponsor of the development program to
ensure return on investment with sales. Patents based on
“product” or “composition-of-matter” not only give the
patentee the right to exclude others from making and selling
the drug for the same purpose as the patentee but also block the
marketing of any new use that another party discovers. The patent
process also runs alongside extensions of exclusivity built into
some regulatory processes. In contrast, so-called “use” patents
protect a selected therapeutic use. Repurposed drugs fall into four
categories based on those described by the Discovering New
Therapeutic Uses for Existing Molecules initiative of National
Institute of Health (NIH) through the National Center for
Advancing Translational Sciences (NCATS) (https://ncats.nih.
gov/ntu): 1) Therapeutic assets (of any modality) with
remaining patent life but never approved for human use; 2)
Therapeutics with remaining patent life that are currently
approved for one or more indication(s) but have potential use
in others; 3) Therapeutic assets with no patent life that are not
currently marketed because they were either never approved or
were withdrawn; 4) Therapeutics with no patent life currently
manufactured by generic companies, approved for certain
indications, and available by prescription from healthcare
providers. The first two can be developed by the patent holder
or licensed to another company for development; the second two
can be developed by establishing a “use” if it fits patentable
criteria of being sufficiently novel, useful, and non-obvious. All
types of products must meet all the normal benefit-risk
assessment requirements of drug regulation based on the
evidence of quality, safety and efficacy and with appropriate
prescriber information, if they are to be distributed to the
public. In addition, compliance with health technology
assessment (HTA) to oversee pricing and reimbursement
and the way the product is positioned in national guidance
for standard of care is becoming increasingly important in all
major countries and, to a greater or lesser extent, government
controlled.
Regulation and HTA require one or more clinical trials for the
new indication unless it is an exceptional situation. One such
exceptional situation concerns extremely rare conditions, such as
anthrax and Ebola, which can be registered on animal data and
human safety data from healthy volunteers or other indications.
An example of this is Anthrasil™, Anthrax Immune Globulin
Intravenous (Human), approved by FDA in 2015 to treat patients
with inhalational anthrax in combination with appropriate
antibacterial drugs already registered under the animal rule.
Another exceptional situation concerns a product currently
used for the indication. This applies in Europe as “well-
established use”. When an active ingredient of a medicine has
been used for more than 10 years its efficacy and safety may be
considered well-established. In such cases, marketing
authorization may be based on results from the scientific
literature. There are also regulatory mechanisms for the
active ingredient to be used at a different dose (hybrid
applications) and an example of this is dexamethasone
registered by EMA as Neofordex™ under well-established
use in 2016 for multiple myeloma. Most products, however,
will need more than a single clinical trial to establish the new
indication for repurposing. If the indication is completely
new, repurposed drugs normally start with preclinical
pharmacology, including animal models and safety, aimed
at defining dose and length of treatment, followed by a
translational medicine and a clinical program, similarly to
the approval pathway of a new drug.
Regulatory decisions are made on benefit-risk balance and in a
rapidly evolving pandemic two issues come in to play, namely the
speed of drug approval and the urgency of clinical needs. The
speed of developing treatments to the point of approval is key to
protect patients from the infection as quickly as possible. Drug
development of new biologicals or chemicals, other than vaccines,
takes a minimum of 2–3 years even if there is a candidate that has
shown efficacy in animal trials and have scaled down clinical trials
to 6–12 months. Pre-clinical activities of manufacturing to
establish product quality and the necessary safety studies
normally take at least 2 years before clinical trials can start.
Repurposed drugs, however, could appear on the market after
simply completing one ormore clinical trials. As the medical need
for a drug increases and more patients die from the disease, the
benefit of the drug increases in the assessment of benefit-risk
balance. For new biologicals or small-molecule drugs the risk
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element is not yet established in clinical medicine and it takes
time to accumulate enough patients for this purpose under the
new indication, even if efficacy can be established quickly. A
potential way is to accelerate the generation of evidence to
separate safety trials from efficacy trials, as in medicines and
vaccines registered under the animal rule (Food and Drug
Administration, 2015; European Medicines Agency, 2018). In
United States there is specific guidance for developing products
where efficacy can only be established by the animal rule (FDA,
2015) but in Europe the guidance is included within a specific
guidance for types of development such as the vaccine
guideline (European Medicines Agency, 2018). The
alternative is to use repurposed drugs where the human risk
profile is known.
In situations such as the COVID-19 pandemic, regulatory
agency decisions may have to accelerate their decision process,
thus collaboration and communication between national
regulatory and HTA agencies becomes essential. The aim
should be to reach peak acceleration of review without
compromising the benefit-risk balance assessment. Some
changes in processes may be continued after the pandemic
and it could be argued that they have demonstrated general
improvement in process efficiency such as rolling review in
EMA which has been planned to be extended in their strategy
up to 2025 (European Medicines Agency, 2020b). Some
compromises in process, however, such as monitoring and
audit of clinical trial sites is unique to lockdown and is not
planned to continue.
All drug regulatory agencies have committed to speeding up
regulations and all are collaborating through the International
Coalition of Medicines Regulatory Authorities (ICMRA)
whose website contains valuable information on COVID-19
trial programmes for medicines and vaccines in development.
Each individual agency has also issued guidance which not
only speeds the time to obtain clinical trial approval but also
makes scientific advice more rapidly accessible, dropping
normal agency timelines and conducting video meetings.
With regard to minimal evidence, all major agencies
(Europe, United Kingdom, Japan and the United States)
already had robust processes in place for accelerated
approvals which require minimal evidence. This is
illustrated by remdesivir, a repurposed drug that was
originally developed for Ebola. Remdesivir received Japanese
authorization under the Exceptional Approval Pathway,
Emergency Use Authorization in the USA and in the
United Kingdom access was granted under the Early Access
to Medicine Scheme. Conditional approval for remdesivir by
EMA for use to treat COVID-19 in adults and adolescents with
pneumonia requiring supplemental oxygen was given under
the new accelerated pathway under guidance issued in May
2020 (EMA, 2020). The main efficacy study assessed was
NIAID-ACTT-1 (Beigel et al., 2020) involving 1,063
hospitalized patients with COVID-19 (120 with mild to
moderate disease and 943 with severe disease) showed that
Veklury™ (remdesivir) can speed up the recovery time in some
patients, allowing them to spend less time in hospital or on
treatment. The further clinical data required by EMA is
published in their web site (European Medicines Agency,
2020c; European Medicines Agency, 2020d). In both United
States and EU pediatric data planning is also required. It is
worth noting that although remdesivir use was supported by in
vivo studies due to its initial indication for Ebola virus, it was
trialed in a Phase III clinical trial for Ebola,with that safety data
being also used for the evaluation of the Emergency Use
Approval in the United States (Mulangu et al., 2019).
The expedited drug development and regulatory decision-
making processes may come at the cost of complete drug safety
and effectiveness data. Indeed, the drug development process,
which usually takes 12–15 years, is reduced to 12–18 months or
less. Normally, conducting Phase III clinical trials is a lengthy
process; reducing the time needed so drastically can only be
achieved by conducting shorter, fewer or in extreme cases, no
Phase III clinical trials. This can occur in a pandemic when the
recruitment stage coincides with a period of low incidence of
the disease, such as the trial of remdesivir by Wang et al., which
was stopped early because there were not enough infected
patients available in China to reach trial recruitment targets
(Wang et al., 2020). Therefore, during a pandemic, drugs can
be licensed with less information available than would
normally be acceptable. In the case of COVID-19 it depends
on the prevalence of the disease but repurposed products could
be licensed on the basis of their benefit risk evaluations for
other indications, biomarker data and limited phase III studies
for the COVID-19 indication. Emergency Use Authorization
(FDA), Conditional Marketing Authorization (EMA) or
approval under the Early Access to Medicines Scheme
(MHRA) for COVID-19 were based on very limited clinical
data. Even the full Marketing Authorization are likely to be
granted on the basis of limited clinical data compared to the
conventional licensing requirements. Therefore, real-world
studies to monitor the safety and effectiveness post-
licensing are necessary during a pandemic. Regulatory
decisions are likely to be based on limited Phase III data or
in some circumstances only on the results of Phase II trials
with a conditional license to conduct studies in the post-
marketing phase. It is well known that there are gaps in
available safety information at the time of licensing for all
medicinal products. This is the nature of clinical development
which focuses on efficacy, and is the reason for post-
authorization risk management plans which aim to address
any safety uncertainties during the postmarking phase. Such
uncertainties are significantly higher for products that have
gone through expedited development and licensing. Hence,
robust post-authorization studies with early and regular
interim reporting are not only highly necessary but, in some
cases, may be a condition of the Marketing Authorization.
DRUGS CANDIDATES FOR REPURPOSING
IN COVID-19 INFECTION
To identify drugs being seriously considered for repurposing,
clinicaltrials.gov, a repository for clinical trials, was searched for
all registered clinical trials concerning COVID-19 on July 2, 2020.
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TABLE 1 |Overview of drugs proposed as potential inhibitors of one or more steps of SARS-CoV-2 lifecycle and undergoing experimental studies at 2nd July 2020– source:
clinicaltrials.gov.
Pharmacological class Drug Proposed mechanism in
the treatment of
SARS-CoV-2 infection
Kinase inhibitors Baricitinib It could exert anti-viral effects by its affinity for AP2-associated protein AAK1, reducing
SARS-CoV-2 endocytosis
Imatinib It accumulates in lysosomes resulting in some antiviral activities by lysosomal alkalization
required for virus/cell fusion
Antibacterials Doxycycline It could reduce pro-inflammatory cytokines levels and chelate matrix metalloproteinases
used for cell fusion and viral replication
Antidiabetic drugs Dapagliflozin During virus infection, serum lactate dehydrogenase level excessively rises. Dapagliflozin
has been reported to reduce lactate levels by various mechanisms. It also reduces
oxygen consumption in tissues and causes the use of glucose in the erobic pathway
Linagliptin, sitagliptin Since SARS-CoV-2 could use DPP4 receptor to invade cells, the inhibition of DPP4 could
be useful in mild COVID-19 patients
Antimalarials Artemisinin/artesunate Anti-inflammatory activity, NF-κB-coronavirus effect and chloroquine-like endocytosis
inhibition mechanism
Atovaquone It could inhibit SARS-CoV-2 through targeting of the viral RdRp or 3C-like protease
Chloroquine, hydroxychloroquine They showed interferencewith the glycosylation of ACE-2 receptors; they increase the pH
of acidic cellular organelles, counteracting virus replication
Mefloquine It inhibited SARS-CoV-2 replication in vitro experimental models
Antitumorals Plitidepsin It could inhibit the multiplication and propagation of SARS-CoV-2
Selinexor It could inhibit the replication of SARS-CoV-2 andmediate anti-inflammatory and anti-viral
effects
Antivirals Atazanavir, danoprevir, darunavir Potential SARS-CoV-2 protease inhibition
Clevudine It acts as a potent inhibitor of RdRp protein, preventing RNA replication
Daclatasvir It could target different proteins of the SARS-CoV-2 life cycle, affecting both viral RNA
replication and virion assembly
Emtricitabine RNA synthesis nucleos(t)ide analogue inhibitors could have an effect against SARS-CoV-
2 infection
Favipiravir, galidesivir They inhibit RdRp of RNA viruses, blocking SARS-CoV-2 replication
Lopinavir/ritonavir They could inhibit SARS-CoV-2 replication by blocking 3CLpro and PL2pro proteases
Nelfinavir It may bind to the S trimer structure inhibiting the membrane fusion process
Nitazoxanide It exerts antiviral effects through the phosphorylation of protein kinase activated by
double-stranded RNA, which leads to an increase in phosphorylated factor 2-alpha, an
intracellular protein with antiviral effects
Oseltamivir It could inhibit virus replication and virion release
Remdesivir It could inhibit the RNA synthesis of SARS-CoV-2
Ribavirin It could inhibit SARS-CoV-2 replication
Sofosbuvir It is a chain terminator for SARS-CoV-2 RNA polymerase. In human brain organoids, it
protected from SARS-CoV-2-induced cell death
Tenofovir alafenamide It could inhibit SARS-CoV-2 RdRp
Umifenovir It could block trimerization of the spike glycoprotein, essential for host cell adhesion
Immunosuppressants Cyclosporine It can block viral replication and thus transcription of pro-inflammatory cytokines
Leflunomide In vitro studies have shown antiviral effects of leflunomide against SARS-CoV-2
Sirolimus It could block viral protein expression and virion release
Tacrolimus It inhibited SARS-CoV-2 replication in vitro
Interferons Alpha and beta interferons Interferons exhibit both direct inhibitory effects on viral replication and supporting an
immune response to clear virus infection
Peginterferon lambda-1A It inhibits viral replication without and does not trigger cytokine storm. It helps the body’s
natural immune system into action
Other Amiodarone It could reduce the internal acidity of endosomes and lysosomes affecting cell activities
important for an efficient viral entry
Bicalutamide, bromhexine, camostat mesilate, nafamostat Inhibition of TMPRSS2, an enzyme facilitating SARS-CoV-2 cell penetration
Chlorpromazine It inhibits clatrine-mediate endocytosis by interacting with dynamin
Estradiol patch It could down-regulate ACE2 receptors in kidneys
Famotidine It could bind papain-like protease, responsible for initial processing of the SARS-CoV-2
polyprotein into active subunits
Isotretinoin, retinoic acid They can down-regulate ACE2 receptors; they are potential protease inhibitors; they
could increase CD4 counts
Ivermectin It inhibits the replication of SARS-CoV-2 in vitro
Niclosamide It could block endocytosis of SARS-CoV-2 and prevent its autophagy by inhibition of
S-Phase kinase associated protein 2
Spironolactone It could, theoretically, reduce ACE-2 expression on lung-cell surfaces
Verapamil It could interfere with coronavirus entry and amplification by blocking ion channels
Notes: Drugs involved in safety studies were not included; only drugs approved by regulatory agencies were included. Abbreviations: AAK1, Adaptor-associated protein kinase 1; ACE,
Angiotensin Converting Enzyme; COVID-19, coronavirus disease 2019; DPP4, dipeptidyl-dipeptidase four; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, Severe Acute
Respiratory Syndrome Coronavirus 2; TMPRSS2, Transmembrane protease serine 2.
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Drug Proposed mechanism in
SARS-CoV-2 infection
NSAIDs Acetylsalicylic acid It can inhibit virus replication and platelet aggregation, it has anti-inflammatory and could prevent
lung injury
Indomethacin It could reduce symptoms in COVID-19 patients
Naproxen It could reduce symptoms in COVID-19 patients
Kinase inhibitors Abivertinib, acalabrutinib, ibrutinib, ruxolitinib, anubrutinib To counteract hyper-inflammatory symptoms caused by cytokine storm
Pacritinib It could prevent the development of an inflammatory response to the coronavirus infection and
pulmonary failure
Anaesthetics Isoflurane In vivo studies volatile anaesthetics reduce the severity of ARDS compared to intravenous sedation
Ketamine It may be able to interrupt the inflammation that causes COVID-19 symptoms
Sevoflurane It has anti-inflammatory properties. In vivo studies volatile anaesthetics reduce the severity of
ARDS
Antibacterials drugs Azithromycin, clarithromycin Macrolides can reduce the inflammatory process and modulate the immune system
Antidepressant drugs Fluoxetine, fluvoxamine To counteract hyper-inflammatory symptoms caused by cytokine storm
Anti-thrombotic drugs Alteplase Targeting the coagulation and fibrinolytic systems could limit ARDS progression and reduce
ARDS-induced death
Bemiparin, heparin, rivaroxaban, tinzaparin Prevention of deep vein thrombosis and venous thromboembolism in COVID-19 patients
Bivalirudin Potential option to maintain systemic anticoagulation during extracorporeal membrane
oxygenation
Clopidogrel, prasugrel They could prevent cardiovascular complications in COVID-19 patients
Defibrotide To treat endothelial inflammation in severe COVID-19 patients
Dipyridamole It could reduce D-dimers concentrations and increase lymphocyte and platelet recovery in the
circulation
Enoxaparin It reduces D-dimers concentrations and prevents hemostasis abnormalities
Pentoxifylline It inhibits the synthesis of pro-inflammatory cytokines; it inhibits platelet aggregation and promotes
the fibrinolytic activity
Plasminogen activator Targeting the coagulation and fibrinolytic systems could limit ARDS progression and reduce
ARDS-induced death
Oncologic drugs Duvelisib PI3K inhibition with duvelisib could potentially quell aberrant hyper-activation of the innate immune
system, preferentially polarize macrophages, reduce pulmonary inflammation, and limit viral
persistence
Bevacizumab Suppression of pulmonary edema in COVID-19 patients with ARDS
Etoposide To counteract hyper-inflammatory symptoms caused by cytokine storm
Melphalan Ultra-low doses of melphalan have local and systemic anti-inflammatory effects and decrease the
activation of lymphocytes
Nivolumab Nivolumab-induced immunity normalization could stimulate anti-viral response and prevent ARDS
development
Tetrandrine It could inhibit pulmonary fibrosis
Thalidomide It could reduce the persistent cough and reduce the lung damage by blocking the inflammatory
response
Thymalfasin Administered to individuals with end-stage renal disease, it could reduce the rate and severity of
SARS-CoV-2 infection
Antivirals Isoprinosine It stimulates a non-specific immune response that is independent of the specific viral antigen
Maraviroc It may reverse lymphoid depletion and alter cell trafficking of inflammatory cells, both increasing
viral control capacity and dampening damage to lung tissue, respectively
Glucocorticoids Budesonide, ciclesonide, dexamethasone,
hydrocortisone, methylprednisolone, prednisone
To reduce systemic inflammatory response to SARS-CoV-2 infection
Immunosuppressants Fingolimod It may confine the over-exuberant inflammatory response and slow down the progress of lung
injury
Levamisole It can increase lymphocytes and empower the immunity of the body. It can bind to the SARS-CoV-
2 protease and can decrease the levels of TNF-α and IL-6
Methotrexate It may reduce the over-exuberant inflammatory response and slow down the progress of lung
injury
Olokizumab To counteract hyper-inflammatory symptoms caused by cytokine storm
Ozanimod Its immune-modulating activity could mitigate the morbidity and mortality of COVID-19
Interleukin inhibitors Anakinra, apilimod, canakinumab, clazakizumab, sarilumab,
siltuximab, tocilizumab
To counteract hyper-inflammatory symptoms caused by cytokine storm
Opioids Naltrexone It can reduce production of multiple cytokines, inhibit cellular proliferation of T- and B- cells and
block Toll-like receptor 4
Tramadol It has anti-inflammatory effect decreasing plasma level of TNF-α, which may result in a subsequent
increase in T cell numbers
(Continued on following page)
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Drug Proposed mechanism in
SARS-CoV-2 infection
Other Almitrine To treat COVID-19-induced hypoxic acute respiratory failure
Aviptadil It is a vasoactive intestinal polypeptide (VIP) analogue. In the lug, VIP prevents the activation of
caspases, inhibits IL-6 and TNF-α production and protects against HCl-induced pulmonary
edema
Atorvastatin Inhibition of virus proliferation; it reduced lung virus titers and reduced TNF-α, IL-6 in supernatants
of infected cells
Botulinum neurotoxin It could attenuate chronic cough, dyspnoea, pneumonia, acute respiratory failure, abnormal
circulation, cardiac defects and various neurological deficits
Cholecalciferol Its immunomodulatory effects could prevent the occurrence of respiratory derangement and other
adverse clinical events
Colchicine It reduces cytokine levels as well as the activation of macrophages, neutrophils and the
inflammasome
Conestat alfa It may dampen uncontrolled complement activation and collateral lung damage and reduce
capillary leakage and subsequent pulmonary edema by direct inhibition of kinin-kallikrein system
Crizanlizumab It can decrease inflammation by binding to P-selectin, blocking leukocyte and platelet adherence
to the vessel wall
Deferoxamine Since severe cases of COVID-19 pneumonia have similar clinical presentations of iron overload, it
seems that deferoxamine could be a supportive therapy for resolving the complications of COVID-
19 pneumonia
Dornase alfa It could break down the DNA backbone of neutrophil extracellular traps in the COVID-19 lung
which will promote the degradation of pro-inflammatory extracellular histones and prevent the
amplification of the inflammatory response and the resultant lung dam
Eculizumab It might work as an emergency therapy for the treatment of patients with severe pneumonia or
ARDS associated with COVID-19 infection
Emapalumab To counteract hyper-inflammatory symptoms caused by cytokine storm
Human immunoglobulin It provides passive immune protection against a broad range of pathogens
Ibudilast To decrease COVID-19-related acute respiratory distress syndrome
Iloprost It may improve inflammation and oxygenation in suspected or confirmed COVID-19 patients with
respiratory failure
Infliximab To counteract hyper-inflammatory symptoms caused by cytokine storm
Lanadelumab Blocking the bradykinin 2 receptor and inhibiting plasma kallikrein activity might have an
ameliorating effect on early disease caused by SARS-CoV-2 and might prevent acute respiratory
distress syndrome
Leronlimab To counteract hyper-inflammatory symptoms caused by cytokine storm
Lucinactant It may be able to benefit patients with acute respiratory distress syndrome, improving oxygenation
and lung compliance
Montelukast It can inhibit the signaling of NF-κB, such as interleukin-6,8,10, TNF-α, MCP-1, and other pro-
inflammatory mediators
N-acetylcysteine It can reduce the formation of pro-inflammatory cytokines and also has vasodilator properties by
increasing cyclic GMP levels and by contributing to the regeneration of endothelial-derived relaxing
factor
Nintedanib To treat pulmonary fibrosis in patients with moderate to severe COVID -19
Pamrevlumab It could reduce edema and block fibrotic degeneration of lung tissue in patients with bilateral
COVID-19 pneumonia
Pirfenidone It could inhibit apoptosis, down-regulate ACE receptors expression, decrease inflammation,
ameliorate oxidative stress and protect pneumocytes and other cells from SARS-CoV-2 invasion
and cytokine storm
Poractant alfa It could improve oxygenation and survival in COVID-19 patients with acute distress respiratory
syndrome
Prazosin It prevents cytokine storm and markedly increased survival following inflammatory stimuli in
preclinical models
Progesterone It could reduce the immunity response
Pyridostigmine Acetylcholine-esterase inhibitors may act as immunomodulators during viral infections, potentially
reducing the inflammatory cascade observed in critically ill COVID-19 patients
Ravulizumab It could counteract hyper-inflammatory symptoms caused by cytokine storm
Sargramostim It may confer benefit to patients with ARDS due to COVID-19 exposure, who are at significant risk
of mortality
Sildenafil citrate It inhibits inducible nitric oxide synthase, an enzyme activating a cascade of inflammatory
processes
Tranexamic acid It reduces the elevated levels of plasmin/plasminogen
Ulinastatin It could counteract hyper-inflammatory symptoms caused by cytokine storm
Zilucoplan It can inhibit acute lung injury post COVID-19 and can promote lung repair mechanisms
Notes: Drugs involved in safety studies were not included; only drugs approved by regulatory agencies were included. Abbreviations: ACE, Angiotensin Converting Enzyme; ARDS, Acute
respiratory distress syndrome; COVID-19, coronavirus disease 2019; IL, Interleukin; MCP-1, Monocyte chemoattractant protein-1; PI3K, phosphoinositide 3-kinase; SARS-CoV-2,
Severe Acute Respiratory Syndrome Coronavirus 2; TNF-α, Tumor necrosis factor-alfa.
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Studies aiming to evaluate drug safety were excluded, as were all
studies concerning vaccines. Studies were included irrespectively
of whether they were planned, ongoing or completed, and also
irrespectively of whether the drugs were intended to prevent or
treat COVID-19. For each drug being considered as a treatment
in a clinical trial, the mechanism of action was identified through
a literature search.
Overall, drugs currently being tested for repositioning in
COVID-19 can be distinguished as 1) drugs potentially able to
inhibit one or more steps of the coronavirus lifecycle (Table 1)
and 2) drugs potentially able to counteract the effects of SARS-
CoV-2 infection, such as the amplified immune response and the
massive cytokine release, which both lead to severe complications
such as coagulopathy and acute respiratory distress syndrome
(ARDS) (Table 2). To date, only remdesivir has been approved to
treat COVID-19.
Drugs Inhibiting One or More Steps of
SARS-CoV-2 Lifecycle
Virus Attachment and Entry
The first targetable step of SARS-CoV-2 life cycle is the entry of
the virus in the host cells. The virus can enter the cells via
endocytosis or via plasma membrane fusion through the
interaction between the Spike (S) protein of the virus and
angiotensin-converting enzyme 2 (ACE2) and transmembrane
protease serine 2 (TMPRSS2) at target cell (Fehr and Perlman,
2015). Specifically, it has been demonstrated that SARS-CoV-2
binds to ACE2 receptors for entry and uses TMPRSS2 for S
protein priming, which is essential for the binding to its receptor
(Hoffmann et al., 2020). A number of molecules hypothesized to
down-regulate ACE2 receptors such as estradiol, spironolactone,
isotretinoin and retinoic acid, as well as the TMPRSS2 inhibitors
bicalutamide, camostat mesilate and nafamostat were therefore
proposed as potential treatments for COVID-19 patients.
Furthermore, much attention is being paid to two antiviral
drugs potentially inhibiting the binding of SARS-CoV-2 to
host cells: umifenovir, which could block the trimerization of
the S protein, and nelfinavir, which may bind to the S trimer
structure inhibiting the membrane fusion process. It has also been
hypothesized that human dipeptidyl peptidase 4 (DPP4) could be
a functional receptor for the S protein of SARS-CoV-2, which in
turn led to the hypothesis that DPP4 inhibitors may play a role in
preventing and reducing the risk and progression of COVID-19
(Iacobellis, 2020). As stated above, SARS-CoV-2 can also enter
the cells via endocytosis, a transport mechanism by which the
virus is enveloped by the cell membrane and enters the cell within
a vesicle. Drugs potentially inhibiting the endocytosis, e.g., the
antimalarials chloroquine, hydroxychloroquine, amodiaquine,
artemisinin and artesunate baricitinib, chlorpromazine,
niclosamide, imatinib and amiodarone and the antimalarials
have been therefore proposed to inhibit the entry of SARS-
CoV-2 in the host cells. The main proposed mechanisms for
the inhibition of endocytosis are: 1) the inhibition of endocytic
proteins (e.g., clathrins, adaptor-associated protein kinase 1 and
dynamin); 2) the accumulation in acid vesicles and, therefore, the
inhibition of viral entry when the endocytosis is pH dependent.
Viral Replication
The second step in SARS-CoV-2 lifecycle is the replication of viral
RNA from an RNA template, catalyzed by the RNA-dependent
RNA polymerase (RdRp) (Fehr and Perlman, 2015). Drugs able
to inhibit this enzyme, such as the antiviral drugs favipiravir,
galidesivir, tenofovir, sofosbuvir and clevudine, and antivirals
inhibiting the replication of RNA, e.g., remdesivir, emtricitabine
have been proposed as candidates for repurposing in COVID-19.
Interferons (alfa interferon, beta interferon and peginterferon
lambda) are also currently being evaluated as viral replication
inhibitors and promoters of immune response to clear virus
infection. Viral RNA replication is followed by RNA
translation and proteolytic processing of viral proteins.
Protease inhibitors currently used to treat human
immunodeficiency virus and acquired immune deficiency
syndrome (HIV/AIDS) such as atazanavir, danoprevir,
darunavir, lopinavir and ritonavir and the immunosuppressant
levamisole have been therefore proposed as potential treatments
to inhibit SARS-CoV-2 replication. Tetracycline derivatives such
as doxycycline have also been proposed as candidates for
repurposing in COVID-19, due to their potential to chelate
metalloproteinases used by coronavirus for cell fusion and
virus replication.
Virion Assembly and Release
Once the viral structural proteins are synthetized and processed,
they are assembled to form new virus particles called virions.
They are subsequently transported to the cell surface in vesicles
and then released by exocytosis (Fehr and Perlman, 2015). Thus,
antiviral drugs acting on this step of viral replication such as
oseltamivir and daclatasvir have been proposed for repurposing
for COVID-19 treatment, along with other drugs like the
immunosuppressant sirolimus.
Drugs Potentially Counteracting the Effects
of SARS-CoV-2 Infection
As stated above, SARS-CoV-2 infection can be associated with
amplified immune and inflammatory response leading to an
uncontrolled cytokine release, known as cytokine storm,
especially in its severe form. The cytokine storm is in turn
associated with complications like ARDS, macrophage
activation syndrome (MAS), lymphopenia and coagulopathy,
representing one of the most studied targets to find an
effective treatment for COVID-19 patients (Crisafulli et al.,
2020). This is the reason why a number of anti-inflammatory
and immunomodulatory drugs like non-steroidal anti-
inflammatory drugs (NSAIDs), glucocorticoids, kinase
inhibitors and interleukin antagonists are being evaluated to
be repositioned in COVID-19. Specifically, these drugs could
reduce systemic inflammatory symptoms and counteract
cytokine storm effects. Dexamethasone in particular has been
evaluated for its ability to counteract the effects of SARS-CoV-2
infection and was the subject of several trials. Indeed, a meta-
analysis of seven trials found that dexamethasone was associated
with a lower risk of mortality at 28 days (odds ratio  0.64 [95%
confidence interval: 0.50–0.82]) in critically ill COVID-19
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patients, compared to placebo or standard of care (Sterne et al.,
2020). Anti-inflammatory and immunomodulatory effects have
been postulated also for macrolide antibiotics such as
azithromycin and clarithromycin (Sultana et al., 2020a).
To treat respiratory complications due to SARS-CoV-2
infection such ARDS, several drugs approved for the treatment
of idiopathic pulmonary fibrosis such as nintedanib, pirfenidone
and pamrevlumab have been proposed. Other drugs currently
being evaluated as candidates for repositioning in COVID-19-
induced ARDS are bevacizumab, aviptadil, eculizumab and
conestat alfa, due to their potential to reduce pulmonary
edema. Coagulopathy is another of the main complications of
COVID-19-triggered cytokine storm, suggesting the potential
role of anti-thrombotic agents to prevent venous
thromboembolism. Coagulation is activated by the
inflammatory response through several pro-coagulant
pathways (Connors and Levy, 2020) and it presents with a
considerable increase of D-dimer levels that could be
ascribable to the attempt of the fibrinolytic system to remove
fibrin and necrotic tissue from the lung parenchyma (Medcalf
et al., 2020). Indeed, it has also been suggested that fibrinolytic
therapy may be an effective pharmacological strategy to treat
acute lung injury in COVID-19 patients (Liu et al., 2018). Based
on these considerations, tissue-plasminogen activator and
alteplase are currently being investigated in experimental
studies for repurposing in COVID-19 patients. Finally, it is
interesting to note that some approved drugs with mechanism
of actions that are not immediately associated with COVID-19
have also been proposed as candidates for repositioning.
Examples include general anaesthetics ketamine, sevoflurane
and isoflurane, which are hypothesized to reduce systemic
inflammation and ARDS severity. Further examples include
the antidepressants fluoxetine and fluvoxamine, which are
thought to be potentially able to counteract hyper-
inflammatory symptoms caused by cytokine storm. Another
drug proposed as a potential therapy for COVID-19, although
not yet evaluated in a clinical trial, is the mood stabilizer lithium,
whose antiviral activity was demonstrated at preclinical level, but
it was not confirmed in clinical settings (Murru et al., 2020;
Rajkumar, 2020).
SOURCES OF EVIDENCE FOR THE
BENEFIT-RISK EVALUATION OF DRUGS
FOR REPURPOSING IN COVID-19
Pre-Clinical Studies
Pre-clinical studies are those studies which are conducted
in vitro (in a pathogen, animal or human cells) or in vivo
through animal models prior to the initiation of clinical
studies in patients, whether healthy or sick. They include
studies which are conducted in silico (Elmezayen et al.,
2020), in vitro, such as receptor-binding assays to identify
drug ligands and studies using cell lines or tissues excised
from animals or humans representative of a specific disease,
to evaluate how these biological milieus of varying complexity
respond to a drug. Pre-clinical studies also include those studies
which are conducted in vivo, where animals are exposed to a
particular drug. The animals treated with a drug are then tested
for various biological and/or behavioral parameters and may be
sacrificed for histological examinations. Such animals may be
small models, such as mice or ferrets, or larger models, such as
non-human primates. A compendium of existing animal models
used for COVID-19 research is available in the public domain
(National Center for Advancing Translational Sciences, 2020).
Taken together, pre-clinical studies can be useful in drug
repurposing in the phase of hypothesis generation. Through
these studies, the pharmacological mechanism of a drug in a
novel context, in this case in SARS-CoV-2 infection can be
better understood. This is important to attribute a degree of
biological plausibility to the hypothesized effect of a drug in a
new indication, as indeed, all indications of repurposed drugs
are de facto new.
Ideally, pre-clinical studies in a repurposing context should
specifically concern the effects of a drug in the disease for which
repurposing is being attempted. For example, pre-clinical studies
to support the repurposing of an anti-viral drug for SARS-CoV-2
should be conducted using microbiological assays, or cell lines
and animal models which have been infected with the agent of
interest, i.e., SARS-CoV-2. However, this presupposes an accurate
knowledge of the disease pathology and symptoms, which may be
problematic in a novel disease such as COVID-19. If the
biological and clinical aspects of the disease which are critical
determinants of clinical outcomes are not known, they cannot be
measured and identified as therapeutic targets, even in a pre-
clinical setting. Direct pre-clinical evidence of the infectious agent
of interest may also be limited during a pandemic for several
reasons. First, the virus has to be isolated, described and cultured
before it can be sent to laboratories, unlike other microbial agents
which are already known and available in vitro. Secondly, while in
vivo experiments are higher up the evidence hierarchy than
in vitro experiments because they represent a complex living
organism rather than isolated cells of tissues, the pathology of
SARS-CoV-2 may be different in animals as compared to
humans. As a result, the safety and efficacy of drugs in vivo
may not be generalizable to humans. Some animal models may
need to be specifically developed to address a particular
hypothesis and may not be available on large scale. One
example is the transgenic mouse model which produces the
human ACE2 protein, needed to conduct pre-clinical studies
concerning renin-angiotensin-aldosterone system (RAAS)
inhibitors, such as angiotensin converting enzyme inhibitors
(ACEIs) and angiotensin receptor blockers (ARBs) (Callaway,
2020). Once developed, the effect of the virus in the mouse model
needs to be described in detail for it to be accepted as a valid
model of the disease (Bao et al., 2020; Jiang et al., 2020). Only then
can pharmacological testing be considered potentially
informative. In the absence of in vitro and in vivo models of
SARS-CoV-2, models of other related infective agents can be and
have been considered but their relevance to the disease of interest
may be ambiguous. An example is how to support the biological
plausibility of azithromycin, an antibiotic, being clinically useful
in COVID-19, caused by a virus, is based on its ability to modify
the reaction of the immune system and to reduce inflammation
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(Kanoh and Rubin, 2010; Parnham et al., 2014; Cramer et al.,
2017) in a pre-clinical setting. This information was not derived
directly from SARS-CoV-2 infections. The effectiveness of
azithromycin in a clinical setting has not been proved to date
(Sultana et al., 2020a).
Pre-clinical studies can be useful because they can provide
results in a relatively short time compared to clinical studies
concerning whether a particular pharmacological approach is
likely to be worth pursuing. However, the information they can
provide on drug safety and efficacy is very limited because pre-
clinical studies necessarily provide an incomplete picture of
disease pathology as well as potentially generating contrasting
findings. The real value of pre-clinical evidence must be proven in
a clinical setting. ACEIs and ARBs are a good example of how
pharmacological evidence derived from a pre-clinical setting is
not always directly translatable to the clinical setting. Pre-clinical
evidence on these drugs was not consistent to begin with, with
some research suggesting that based on their pharmacological
interaction with the virus, that they will worsen prognosis after
SARS-CoV-2 infection and/or increase the risk of infection (Fang
et al., 2020; Gurwitz, 2020; Zheng et al., 2020), and other research
findings concluding that they are likely to be protective (Gurwitz,
2020). Ultimately, in several observational studies of infected
patients it was seen that ACEIs and ARBs are likely to be neither
(Li et al., 2020a; de Abajo et al., 2020; Feng et al., 2020; Fosbøl
et al., 2020; Gao et al., 2020; Mancia et al., 2020; Mehta et al., 2020;
Meng et al., 2020; Reynolds et al., 2020; Selçuk et al., 2020; Yang
et al., 2020; Zhang et al., 2020). Another example concerns
hydroxychloroquine, which was found to inhibit SARS-CoV-
2 in vitro (Liu et al., 2020) but not found yet to be effective in
clinical practice (Geleris et al., 2020), either as treatment or as
post-exposure prophylaxis (Boulware et al., 2020). Another
important role of pre-clinical studies is to evaluate the
pharmacokinetic profile of a potential drug candidate, in order
to ensure that the effective doses in animal models can be
translated safely to humans.
Clinical Trials
Clinical trials, ranging from single-arm open-label trials to
randomised controlled trials (RCTs) provide information on
drug tolerability and, most importantly, efficacy. RCTs are
considered the gold standard of evidence generation on drug
efficacy because randomization of treatment randomly
distributes potential confounders among treated and untreated
patients. The masking of participants, investigators, and/or
outcomes assessor to treatment assignment further increases
the reliability of results by preventing bias. The clinical
information that trials can provide concerning potentially
repurposable drugs for SARS-CoV-2 varies widely and can
refer to very specific indications such as post-exposure
prophylaxis (NCT04321174 - lopinavir/ritonavir RCT),
treatment of mild COVID-19 (NCT04342663 - fluvoxamine
RCT) and treatment of hospitalized patients with COVID-19
(NCT04280705 - remdesivir RCT) as well as critically ill
hospitalized patients specifically (NCT04244591 -
methylprednisolone RCT). This has implications for the
generalizability of study results and the application of findings
in clinical practice. To address this issue, both the FDA and the
World Health Organization (WHO) have published guidance on
the recommended standards in drug development and clinical
research in COVID-19 (Food and Drug Administration, 2020b;
Marshall et al., 2020b).
Although serendipitous drug rediscovery is possible, it is
perhaps more likely that drugs with a consolidated
pharmacological target in the disease of interest have a higher
chance of successfully getting through trials, not least because this
may impact the choice of appropriate outcomes. An example of a
drug which is not supported by a strong pharmacological
rationale is fluvoxamine, currently being tested for the
treatment of non-hospitalized persons with COVID-19
(NCT04342663 - fluvoxamine RCT). Another example is
estradiol, where evidence is still emerging (Li et al., 2020b),
currently being tested among persons with suspected or
confirmed COVID-19 to evaluate whether it reduces the
severity of symptoms (NCT04359329 - estradiol patch RCT).
These examples highlight the complementarity of pre-clinical and
clinical studies in drug repurposing as in drug discovery, because
pre-clinical evidence can suggest the biological plausibility of a
drug being effective while the clinical evidence is needed to
confirm that a drug is effective and safe.
Conducting methodologically sound trials during a pandemic
can be challenging, for scientific, logistical and ethical reasons
(Angus, 2020) and rapid dissemination of poor quality studies
can have serious consequences (Kim et al., 2020). Some issues
highlight the need to interpret the available clinical trials with
great care. Not all trials are created equal and there is an accepted
hierarchy of quality. Open-label trials, such as an ongoing trial for
ruxolitinib in combination with simvastatin (NCT04348695 -
ruxolitinib in combination with simvastatin RCT) in such a
highly charged situation as a pandemic may lead to bias, as
compared to double-blind trials (Wang et al., 2020). Similarly,
clinical studies lacking randomization (NCT04304313 - sildenafil
non-randomized trial) are considered much less reliable
than studies randomizing treatment (NCT04350593 -
dapagliflozin RCT).
Patient recruitment can be more problematic when organizing
a trial during a pandemic than it would otherwise be. The size of a
study population can limit the scope of causal inference if a trial is
underpowered. There are currently ongoing trials to repurpose
drugs which aim to recruit as little as 10 patients (NCT04304313 -
sildenafil non-randomized trial). Restrictive inclusion and
exclusion criteria may not only lead to an under-powered
study but also to a patient population that is not
representative of the real-world setting. For example, in a
randomized double-blind trial of fluvoxamine in COVID-19,
patients with severe underlying respiratory disease were
excluded, as were patients with dementia, as these could not
provide informed consent (NCT04342663 - fluvoxamine RCT). A
broader population would only be included in phase III trials.
While such exclusion criteria are necessary for the purpose of
causal inference and to respect patients’ right to self-
determination, lack of this data in phase III confirmatory trials
may limit the generalizability of study findings by excluding
patients who are at highest risk of contracting COVID-19
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and/or developing severe symptoms as well as of developing
adverse drug effects. Even patient follow-up can be problematic
during a pandemic. Some researchers have resolved this issue by
conducting trials remotely, for example completely avoiding face-
to-face encounters, with study material, including the study drug,
being delivered to patients’ homes (NCT04342663 - fluvoxamine
RCT). This could be a problem for taking into account patient
compliance and is likely to be more viable for cases of COVID-19
which are treated at home, however use of digital
communications such as text messaging, teleconference
programs and couriers has largely overcome this. While ideally
a clinical trial should be conducted according to a strict protocol,
there are ethical implications in continuing to treat patients with a
comparator drug if the main study drug appears to be effective.
Indeed, some trials explicitly state that should interim results
suggest a study drug is effective, it will be considered the new
control (NCT04280705 - remdesivir RCT). Small controlled trials
are considered to be less useful when evaluating drug safety but
this is potentially less of a problem with drugs which have already
been approved, because their safety profile is likely to have already
been well-described. Indeed, this is the main advantage of
repurposing drugs as opposed to de novo drug discovery.
However, because of their limitations clinical trials must be
complemented by observational studies conducted in a real-
world setting.
A variant of clinical trials worth mentioning, a hybrid between
trial design and observational study design, is the adaptive trial. In
adaptive trials, a review and adapt approach is used while the trial
is being conducted, as opposed to the linear approach used in
classical trials, where the trial occurs in three distinct phases,
i.e., trial design, implementation and analyses (Pallmann et al.,
2018). As a result, certain changes can be made to trial design and
analytic plans based on preliminary data. Such a study design can
be very valuable in the pandemic setting because new findings are
constantly emerging and standards of care are rapidly changing.
Some examples of adaptive trials being carried out to evaluate
drug efficacy and safety for COVID-19 treatment include the
REMAP-CAP (Angus et al., 2020), WHO SOLIDARITY trial
(World Health Organization, 2020) and RECOVERY trials
(Horby et al., 2020).
There is a notable interplay between regulatory and
government bodies and researchers conducting clinical trials,
as such entities have a role in regulating clinical trials. An
example is the ACTIV/Operation Warp Speed groups in the
United States that are coordinating pre-clinical studies and
clinical evaluation of interventions to advance the most
promising candidates given the limited resources available,
including animals for pre-clinical evaluation and patient
population for clinical evaluation.
Observational Studies
While clinical studies are useful to evaluate drug efficacy, they
may not be able to provide evidence rapidly and on a large scale,
as they are contingent on the speed of prospective data collection
and analysis. During a pandemic, time is of essence and public
health authorities cannot wait for weeks until trial results get
published. Observational studies have an important role to play in
this regard because they rely either on data which has already
been collected or on data which is collected quickly in a
prospective manner using previously established data systems
and can therefore be conducted rapidly. They should be
conducted alongside prospective controlled clinical trials which
establish pharmacological basis of evidence. The main role of
observational studies in evidence generation concerns drugs
which are used off-label for COVID-19. For example, a
retrospective observational study was carried out in a hospital
in Lombardy, Italy, to evaluate the effectiveness of anakinra in
improving clinical outcomes among patients infected with
COVID-19, finding that this IL-1 antagonist was effective
(Cavalli et al., 2020). Similarly, an observational study was
conducted in hospitals of the Bologna and Emilia-Romagna
areas in Italy, to assess the effectiveness of tocilizumab in
improving clinical outcomes among patients with COVID-19,
also finding that this drug is potentially effective (Campochiaro
et al., 2020). It was also observational studies which were able to
rapidly shed light on lack of effectiveness of RAAS inhibitors in
improving clinical outcomes in COVID-19 (Li et al., 2020a; de
Abajo et al., 2020; Feng et al., 2020; Fosbøl et al., 2020; Gao et al.,
2020; Mancia et al., 2020; Mehta et al., 2020; Meng et al., 2020;
Reynolds et al., 2020; Selçuk et al., 2020; Yang et al., 2020; Zhang
et al., 2020). Another example yet is an observational study which
showed that drugs used to treat prostate cancer, androgen-
deprivation therapies, may have a protective effect among
persons with COVID-19 (Montopoli et al., 2020).
Observational studies have other advantages in addition to the
speed of data collection and large sample sizes. The populations
identified in these studies are a reflection of real-world patients,
including those patients who are likely to be excluded by
trials—children, the very old, persons with serious underlying
respiratory diseases and persons with a large number of
concomitant medications (Sultana et al., 2013).
To date, there are 50 studies concerning COVID-19 recorded
in the EU post-authorization study (PAS) register, the official
European repository of PAS. The PASs for a repurposed product
in a pandemic depend on the potential and identified risks, as well
as the important missing information identified during pre-
marketing. While the gaps in the safety and effectiveness
information at the time of licensing are greater for a
repurposed product that has been developed expeditiously, the
principles are similar to conventional products. Research
questions need to be formulated based on the public health
needs and the available pre-marketing data. The next task will
be selecting the most appropriate study approach (primary or
secondary data collection), study setting or data resource and
study design (cohort, case-control, nested case-control, cross
sectional or in some cases simple randomised clinical trial).
Open extensions of post-marketing clinical trials are an
important method which will be used frequently. Situations
where the incidence and prevalence of cases is low present a
challenge; a solution is to conduct the studies in countries with
higher incidence of the infection or extending the study
population by conducting multi-country studies. The sample
size of studies spanning several countries is typically larger
than those restricted to a single country, meaning that the
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target recruitment is generally achieved more quickly and results
are available faster. Multinational studies do not only report the
effect of the drug but also reflect the nature and delivery of the
healthcare system in the different countries. This in turn has an
impact on the conduct of the studies, as certain types of health
information may not be available in the same way in all study
countries. This includes information such as exposure, outcomes,
confounders and previous medical history. However, this is not
an insurmountable issue because one of the key points of studies
conducted in a network of countries is that the master study
protocol can bemodified to take account of different data sources.
Depending on the heterogeneity or similarity of the information
available, results can be meta-analyzed or pooled with data from
different sources with the same objectives. Multi-database studies
are becoming increasingly important as their potential in
reaching large sample sizes over a short observation period is
recognized (Gini et al., 2020). Indeed, it is internationally
acknowledged that having a stable multi-database network to
rapidly provide almost real-time healthcare information to
regulatory and public health agencies is very important
(Sultana et al., 2020b). This potential is highlighted in a public
health crisis such as the COVID-19 pandemic.
Of course, observational studies also have their limitations.
Since they are often conducted using sources of secondary data,
i.e., data not intended primarily for research purposes, the
quality of the data must be thoroughly checked as it can
contain errors in data entry, such as incomplete data,
Anatomic Therapeutic Chemical (ATC) classification codes at
a lower level than the fifth level, missing data, such as sex, or
clearly implausible data, such as date of birth set in the future.
Furthermore, diagnosis data in secondary data sources may be
of limited reliability and there may be underestimation of
certain diseases based on the context in which coding is
assigned. For example, acute conditions are likely to be better
captured in secondary data sources such as hospital claims while
chronic conditions are likely to be better captured in primary
care electronic records (Trifirò et al., 2019). In the case of
COVID-19 specifically, observational studies may be limited
by the extent to which they can reliably identify patients who
have a microbiologically ascertained diagnosis of COVID-19.
Finally, unlike classical clinical trials, observational studies
cannot ascertain that a prescribed or dispensed drug was
truly administered. This is assumed to be the case, but in the
context of a pandemic, it is possible that patients may not
actually go to fill their prescriptions.
CONCLUSION
Several drugs are currently being studied as potential
repurposing candidates in clinical trials, but to date only
remdesivir has been approved for the treatment of COVID-
19. Although drug repurposing has the potential to decrease the
time usually required for a drug to reach the market, it is a
process that is still associated with many challenges, whether
from a regulatory or a scientific perspective. Close collaboration
between various stakeholders is needed to leverage and critically
evaluate existing evidence and strategically plan the generation
of new pre-clinical, clinical and observational evidence to
investigate the efficacy/effectiveness and safety of drug for
potential repurposing. One of the main objectives of such a
collaboration should be to avoid duplication of studies and plan
studies in such a way that the outcomes evaluated can be
compared. Pre-clinical, clinical and observational research all
generate complementary information which is necessary in
building the case for drug repurposing.
AUTHOR CONTRIBUTIONS
GT conceived the study. JS, SC, FG, EL, and SS wrote the first
draft of the paper.
REFERENCES
Angus, D. C. (2020). Optimizing the trade-off between learning and doing in a
pandemic. JAMA 323, 1895–1896. doi:10.1001/jama.2020.4984
Angus, D. C., Berry, S., Lewis, R. J., Al-Beidh, F., Arabi, Y., van Bentum-Puijk, W.,
et al.. (2020). The REMAP-CAP (Randomized embedded multifactorial
adaptive platform for community-acquired pneumonia) study. Rationale
and design. Ann. Am. Thorac. Soc. 17, 879–891. doi:10.1513/annalsats.
202003-192sd
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., et al. (2020). The
pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583,
830–833. doi:10.1038/s41586-020-2312-y.
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A.
C., et al. (2020). Remdesivir for the treatment of covid-19— preliminary report.
N. Engl. J. Med. [Epub ahead of print]. doi:10.1056/nejmoa2007764.
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M.,
Okafor, E. C., et al. (2020). A randomized trial of hydroxychloroquine as
postexposure prophylaxis for covid-19. N. Engl. J. Med. 383, 517–525. doi:10.
1056/nejmoa2016638.
Callaway, E. (2020). Monkeys and mice enlisted to fight coronavirus. Nature 579,
183. doi:10.1038/d41586-020-01179-x.
Campochiaro, C., Della-Torre, E., Cavalli, G., De Luca, G., Ripa, M., Boffini, N.,
et al. (2020). Efficacy and safety of tocilizumab in severe COVID-19 patients: a
single-centre retrospective cohort study. Eur. J. Intern. Med. 76, 43–49. doi:10.
1016/j.ejim.2020.05.021.
Cavalli, G., De Luca, G., Campochiaro, C., Della-Torre, E., Ripa, M., Canetti, D.,
et al. (2020). Interleukin-1 blockade with high-dose anakinra in patients with
COVID-19, acute respiratory distress syndrome, and hyperinflammation: a
retrospective cohort study. Lancet Rheumatol. 2, e325–e331. doi:10.1016/
S2665-9913(20)30127-2.
Connors, J. M., and Levy, J. H. (2020). COVID-19 and its implications for
thrombosis and anticoagulation. Blood, 135, 2033–2040. doi:10.1182/blood.
2020006000.
Cramer, C. L., Patterson, A., Alchakaki, A., and Soubani, A. O. (2017).
Immunomodulatory indications of azithromycin in respiratory disease: a
concise review for the clinician. Postgrad. Med. 129, 493–499. doi:doi:10.
1080/00325481.2017.1285677.
Crisafulli, S., Isgrò, V., La Corte, L., Atzeni, F., and Trifirò, G. (2020). Potential role
of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: rationale,
clinical evidence and risks. BioDrugs 34, 415–422. doi:10.1007/s40259-020-
00430-1.
de Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., García-
Luque, A., et al. (2020). Use of renin–angiotensin–aldosterone system inhibitors
Frontiers in Pharmacology | www.frontiersin.org November 2020 | Volume 11 | Article 58865411
Sultana et al. Drug Repurposing for COVID-19
and risk of COVID-19 requiring admission to hospital: a case-population study.
Lancet 395, 1705–1714. doi:10.1016/S0140-6736(20)31030-8.
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